Jennison Associates

Jennison Associates’s CRISPR Therapeutics CRSP Stock Holding History

Jennison Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-409,683	Closed	-$31M	–	645
2021 Q4	$31M	Sell	409,683 -7,297	-2%	-$637K	0.02%	290
2021 Q3	$46.7M	Buy	416,980 +141,769	+52%	+$17.8M	0.03%	230
2021 Q2	$44.6M	Hold	275,211	–	–	0.03%	239
2021 Q1	$33.5M	Sell	275,211 -2,083	-0.8%	-$315K	0.02%	280
2020 Q4	$42.5M	Sell	277,294 -2,807	-1%	-$332K	0.03%	230
2020 Q3	$23.4M	Buy	280,101 +913	+0.3%	+$81K	0.02%	283
2020 Q2	$20.5M	Buy	279,188 +102,689	+58%	+$6M	0.02%	288
2020 Q1	$7.49M	Buy	+176,499	New	+$9.11M	0.01%	363
2018 Q4	–	Sell	-540,887	Closed	-$24M	–	661
2018 Q3	$24M	Buy	+540,887	New	+$28.3M	0.02%	369

Other funds holding CRSP

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return